<DOC>
	<DOCNO>NCT00314821</DOCNO>
	<brief_summary>To demonstrate efficacy safety Requip bipolar disorder , depressive state .</brief_summary>
	<brief_title>Ropinirole Treatment Bipolar Depression</brief_title>
	<detailed_description>Primary outcome group difference Requip placebo random effect linear regression analysis . The secondary outcome include predictor response , insight illness , comorbid anxiety symptom , prior course illness , previous treatment history antidepressant , relevant clinical demographic feature .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Meet DSMIV criterion bipolar disorder , type II Current MADRS score &gt; 16 Current MRSSADS score &lt; 10 Prior participation study , subject must sign informed consent . All patient require also take least one moodstabilizing agent , define standard agent ( lithium , valproate , carbamazepine ) novel anticonvulsant agent ( oxcarbazepine , gabapentin , topiramate ) . If patient take agent study initiation , require start one agent least two week study initiation . Study inclusion criterion must meet least 2 week treatment one moodstabilizing agent . Any serious acute medical illness Any clinically serious evidence suicidality score 3 great suicide item MADRS scale</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>bipolar disorder , ropinirole , depression</keyword>
</DOC>